EPRX: Once-yearly therapy for EoE targets compliance and durability, with pivotal data due in December
EoE is a rapidly growing market with significant unmet needs, and a once-yearly, physician-administered therapy is positioned to address compliance and durability challenges. Interim Phase IIb data in December will provide detailed efficacy and safety insights, supporting expansion into related ind…